The invention relates to the field of therapeutic and diagnostic tools for use in Oncology. In particular, it relates to a peptide comprising at least 8 amino acids in length, which are present as adjacent amino acids in the amino acid sequence of human isocitrate dehydrogenase type 1 (IDH1), where said peptide has at least one amino acid substitution R for H in the position position 132, for use in the prevention and / or treatment of cancer. Additionally, a drug product is proposed that includes said peptide. In addition, the invention relates to a cancer diagnosis method characterized by the presence of a mutation in the genome of at least some cancer cells, which results in the expression of the mutant IDH1 gene having the mutation R132H. The method includes the steps of contacting a sample of a subject’s blood sample, which is presumed to be suffering from such a cancer, with a peptide comprising at least 10 amino acids in length that are present as contiguous amino acids in the amino acid sequence IDH1, where said peptide has at least one amino acid substitution of R for H in the position corresponding to position 132, for a period of time and under conditions that allow specific binding of a component of the immune system to a peptide, and Ia occurred or not the binding of said immune system component with the peptide, wherein the cancer is diagnosed, if confirmed by the presence of binding. The invention also provides a kit and apparatus for carrying out the method.Изобретение относится к области терапевтических и диагностических средств для применения в онкологии. В частности, оно относится к пептиду, включающему по меньшей мере 8 аминокислот в длину, которые присутствуют в виде смежных аминокислот в аминокислотной последовательности человеческой изоцитратдегидрогеназы типа 1 (IDH1), где упомянутый пептид имеет по меньшей мере одну аминокислотную замену R на Н в положении, соответствующем позиции 132, для применения при профилактике и/или лечении раковых за
